Adjuvant Treatment...Useful in Certain Circumstance...Pilocytic astrocytoma, PXA, ganglioglioma if BRAF V600E activating mutation…dabrafenib…

TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.

Retrospective description of three cases of childhood brainstem ganglioglioma with BRAFV600E mutation treated in the long-term with Dabrafenib, a specific BRAFV600E kinase inhibitor….Dabrafenib resulted in rapid tumoral regression and significant and durable clinical and radiological improvement....This targeted therapy has been well tolerated despite its long-term use of 4.8 to 5.5 years in the three patients.

Three patients with recurrent ganglioglioma and positive for the V600E mutation were treated with dabrafenib, a second-generation BRAF inhibitor...Best radiographic response following two cycles of dabrafenib was stable disease in two patients and partial response in one patient....Median progression-free survival was 7 months (range 4-10 months). Median overall survival from onset of dabrafenib was 12 months (range 6–16 months).